Document Detail


Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel-Carboplatin Chemotherapy? A Retrospective Study.
MedLine Citation:
PMID:  23154549     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
INTRODUCTION: : Early prediction of the efficacy of a combination of an antiangiogenic drug with cytotoxic chemotherapy is a significant challenge. In that regard, circulating endothelial cells (CECs) and cytokeratins (CKs) seem to reflect their roles in both tumor angiogenesis and tumor cell death.
METHODS: : Patients with advanced, previously untreated non-small-cell lung cancer were randomly assigned to an endostatin treatment group (paclitaxel + carboplatin + endostatin) and a control group (paclitaxel + carboplatin + placebo). A total of 122 patients were evaluated, of whom 107 had measurements of blood CECs, CK8, caspase-cleaved CK18 (ccCK18), and uncleaved CK18 (CK18) before and at weeks 3 and 6 of treatment, respectively.
RESULTS: : Higher baseline CECs in patients with a tumor response (partial remission + stable disease, p = 0.002 for the entire group; p = 0.000 for the treatment group) were observed. The number of CECs decreased significantly after endostatin treatment (p = 0.000), whereas CK levels increased. Increased levels of ccCK18 and CK18, but not CK8, reached significance (p = 0.001 and p = 0.048, respectively) when compared with the baseline. Tumor response showed a strong correlation with reduction of CECs (p = 0.000) and increase of ccCK18 (p = 0.040) after endostatin therapy. Cutoff values of changes of CECs and ccCK18 for prediction of survival were 0.58/μl and 19.6 ng/ml, respectively. Reduction of CECs and increase of ccCK18 significantly correlated with longer median survival (p = 0.013 and p = 0.016 for progression-free survival; p = 0.009 and p = 0.012 for overall survival, respectively).
CONCLUSIONS: : CECs and CKs could be biomarkers for selecting patients with non-small-cell lung cancer who will benefit from treatment with endostatin in combination with paclitaxel plus carboplatin.
Authors:
Tian-Qing Chu; Hao Ding; David H Garfield; Ai-Qin Gu; Jun Pei; Wei-Dong Du; Bao-Hui Han
Related Documents :
24457239 - Outcome and prognostic factors in bronchial carcinoids: a single-center experience.
8774919 - Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to ...
24440279 - A multicenter phase ii study of sorafenib monotherapy in clinically selected patients w...
24859689 - Diagnostic and therapeutic issues for patients with advanced non?small cell lung cancer...
23295799 - Palliative radiation therapy practice in patients with metastatic non-small-cell lung c...
23542459 - Early-stage pulmonary adenocarcinoma (t1n0m0): a clinical, radiological, surgical, and ...
7462019 - Carcinoembryonic antigen in the assessment of lung cancer.
19470929 - Improved survival in metastatic colorectal cancer is associated with adoption of hepati...
9824999 - Comparison of two different radiotherapy schedules for spinal cord compression in prost...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  7     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1781-9     Citation Subset:  IM    
Affiliation:
*Department of Pulmonology, Shanghai Chest Hospital, Jiaotong University, Shanghai, China; †Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital, Fudan University, Shanghai, China; ‡Medical Department, Pro-Med Cancer Centers, Shanghai, China; and §Division of Surgical Oncology and Thoracic Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  FGFR1 amplification in squamous cell carcinoma of the lung.
Next Document:  Prognostic Impact of CD204-Positive Macrophages in Lung Squamous Cell Carcinoma: Possible Contributi...